Drugs / HyperRAB
HyperRAB
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07399951 | Oct 2023 → Jun 2025 | — | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02912845 | Aug 2016 → Nov 2019 | rabies | Kamada, Ltd. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03264157 Comparator | Dec 2017 → Mar 2018 | — | Bio Products Laboratory | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03965962 Background | Jul 2019 → Dec 2020 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HyperRAB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03264157 ↗ |
| Known as | HRIG | “human rabies immunoglobulin (HRIG)” NCT03965962 ↗1“KamRAB - HRIG” NCT02912845 ↗ |
| Known as | Human Rabies Immunoglobulin | “The primary purpose of this study is to confirm the safety of KamRAB (Human Rabies Immunoglobulin) in children ages 0 months to \<17 years, when administered as part of...” NCT02912845 ↗ |
| Known as | KamRAB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02912845 ↗ |
| Known as | Rabies immune globulin (human) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03965962 ↗ |
| Modality | Protein / enzyme biologic | “Human Rabies Immunoglobulin” NCT02912845 ↗ |
| Route | Intramuscular | “wound infiltration or IM injection” NCT02912845 ↗ |